cardiac metabolism, as well, were similar between mutation carriers and noncarriers. Conclusions-Despite a similar afterload, RV function is more severely affected in mutation carriers than in noncarriers. However, these differences cannot be explained by a differential transforming growth factor β, bone morphogenetic protein receptor II signaling, or cardiac adaptation. 
P ulmonary arterial hypertension (PAH) is a rapidly progressive and lethal disease, characterized by an increase in resistance of the pulmonary arterioles, causing an increased right ventricular (RV) afterload. [1] [2] [3] The RV adapts to this increased load via several compensatory mechanisms, but these are not sufficient to prevent progression to RV dysfunction and failure, which is the predominant cause of death in PAH. 4 Intriguingly, this clinical observation suggests that the Background-The effect of a mutation in the bone morphogenetic protein receptor 2 (BMPR2) gene on right ventricular (RV) pressure overload in patients with pulmonary arterial hypertension is unknown. Therefore, we investigated RV function in patients who have pulmonary arterial hypertension with and without the BMPR2 mutation by combining in vivo measurements with molecular and histological analysis of human RV and left ventricular tissue. Methods and Results-In total, 95 patients with idiopathic or familial pulmonary arterial hypertension were genetically screened for the presence of a BMPR2 mutation: 28 patients had a BMPR2 mutation, and 67 patients did not have a BMPR2 mutation. In vivo measurements were assessed using right heart catheterization and cardiac MRI. Despite a similar mean pulmonary artery pressure (noncarriers 54±15 versus mutation carriers 55±9 . Differences continued to exist after treatment. To investigate the role of transforming growth factor β and bone morphogenetic protein receptor II signaling, human RV and left ventricular tissue were studied in controls (n=6), mutation carriers (n=5), and noncarriers (n=11). However, transforming growth factor β and bone morphogenetic protein receptor II signaling, and hypertrophy, apoptosis, fibrosis, capillary density, inflammation, andMay 3, 2016 response to rather than the amount of pressure overload determines the fate of the RV in PAH patients.
Patients with PAH may have an underlying genetic predisposition, in particular, a mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene. [5] [6] [7] [8] [9] [10] [11] BMPR2 mutations are an autosomal dominant cause of PAH with reduced penetrance (14% in men, 42% in women) clinically characterized by a younger age and a more severe hemodynamic compromise at presentation in comparison with patients who have idiopathic PAH. 10, [12] [13] [14] [15] The bone morphogenetic protein (BMP) receptor II encoded by the BMPR2 gene belongs to the transforming growth factor β (TGF-β) superfamily and mutations have been shown to result in a disturbed BMP/TGF-β balance. [16] [17] [18] Decreased BMP receptor II activity leads to an overactivated TGF-β signaling, which stimulates vasculogenesis, intimal hyperplasia, and medial smooth muscle growth in the pulmonary vasculature. 19, 20 In addition, growing evidence suggests a key role for TGF-β signaling in the response to pressure overload of the heart. [21] [22] [23] Although TGF-β signaling is necessary to protect the heart against uncontrolled matrix degradation and dilatation, excessive TGF-β signaling might be detrimental because of maladapted hypertrophy and myocardial dysfunction, as previously described in left heart failure. [21] [22] [23] Furthermore, a recent study by Hemnes et al 24 showed that the RV hypertrophic response was disturbed in pulmonary hypertensive mice carrying a BMPR2 mutation. However, whether RV function and adaptation in PAH patients carrying a BMPR2 mutation differs from PAH patients without an identified BMPR2 mutation remains currently elusive. Therefore, the aim of this study was 2-fold: (1) to determine the effects of a BMPR2 mutation on RV function in PAH patients and (2) to compare the histological and morphological characteristics of RV tissue samples from PAH patients with and without a BMPR2 mutation.
Methods

Study Population
Clinical Study
We retrospectively reviewed patients with pulmonary hypertension seen at the VU University Medical Center (Amsterdam, the Netherlands) between March 1995 and October 2014. Patients were eligible for this study when the results from BMPR2 mutation analysis were available. In total, 123 PAH patients were genetically screened for the presence of a BMPR2 mutation. After the exclusion of 28 patients, 95 patients were included in this study. Twenty-eight patients were carriers of a BMPR2 mutation (mutation carriers), and no BMPR2 mutation was identified in 67 sporadic PAH patients (noncarriers). Patients with a family history of PAH with no evidence of a BMPR2 mutation (n=3) or patients with a genetic mutation linked to pulmonary hypertension other than the BMPR2 mutation (n=5) were excluded from the analysis to avoid the risk of misclassification in the BMPR2 noncarriers group. For comparison, a group of 15 control subjects without PAH family history was included in this study. Controls were selected from referred patients suspected with PAH but in whom the condition was ruled out after right heart catheterization (RHC). A subset of patients was eligible for treatment response analysis ( Figure 1 ). Patients were diagnosed with idiopathic PAH according to current clinical guidelines, by means of RHC and by ruling out all associated conditions of pulmonary hypertension by a multidisciplinary team. 25 All genetically tested patients signed written informed consent and received genetic counseling.
Because the MRI and RHC data were obtained for clinical purposes and analyzed retrospectively, the Medical Ethics Review Committee of the VU University Medical Center did not consider this study to fall within the scope of the Medical Research Involving Human Subjects Act. Therefore, no additional approval was acquired.
Cardiac Tissue Samples
Explanted RV and left ventricular (LV) tissue samples were collected from PAH patients undergoing heart/lung transplantation in the French Referral Center for Pulmonary Hypertension (Université Paris-Sud, France; mutation carriers n=5, noncarriers n=11). Control RV and LV tissue was obtained from nonfailing donors (n=6). Human cardiac tissue collection and use by collaborating universities (VU Medical Center, Amsterdam) was approved by the Human Research Ethics Committee of the Université Paris-Sud -Inserm U999 (ID RBC 2008-A00485-50). Written informed consent was obtained. All samples were stored in paraffin.
Genetic Analysis of the BMPR2 Gene
Genomic DNA was extracted from peripheral blood samples after the patients gave informed consent. The coding sequences and the surrounding splice sites of the BMPR2 gene were amplified by polymerase chain reaction. Polymerase chain reaction amplification was performed by using a PE9700 thermocycle (Applied Biosystems, Forster City, CA). Sequencing reactions were performed by using the Big Dye Terminator system (Applied Biosystems, Forster City, CA) and run on an ABI 3100XL or ABI3730 genetic analyzer (Applied Biosystems, Forster City, CA). To detect deletions and duplications of ≥1 exons, multiplex ligation-dependent probe amplification analysis was performed using MLPA kit P093-A (MRC-Holland, Amsterdam, The Netherlands).
Hemodynamic Measurements
A 7F balloon-tipped Swan Ganz catheter (131HF7, Baxter Healthcare Corp, Irvine, CA) was inserted via the jugular or femoral vein and brought into position under local anesthesia during continuous electrocardiographic monitoring. The following variables were recorded: mean pulmonary artery pressure, right atrial pressure, pulmonary arterial wedge pressure, mixed venous oxygen saturation, and heart rate. Pulmonary vascular resistance (PVR) was calculated via the following formula: 80×(mean pulmonary artery pressure -pulmonary arterial wedge pressure)/cardiac output. Cardiac output was determined by either the Fick method, or thermodilution and stroke volume was calculated as cardiac output divided by heart rate. Both cardiac output and stroke volume were indexed for body surface area, shown as cardiac index and stroke volume index, respectively.
Cardiac MRI
Cardiac MRI was performed on a Siemens 1.5-Tesla Avanto or 1.5-Tesla Sonato scanner (Siemens Medical Solutions, Erlangen, Germany), equipped with a 6-element phased-array coil. A stack of short-axis images were obtained at breath-hold per slice, with a slice thickness and interslice gap of 5 mm, fully covering both ventricles from base to apex.
On end-diastolic images (first cine after R-wave trigger) and endsystolic images (cine with visually the smallest cavity area), endocardial and epicardial contours were manually drawn by using MASS software (Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands) to obtain RV end-diastolic volume, RV end-systolic volume, and RV mass. Volume measurements and RV mass were indexed for body surface area. Papillary muscles and trabeculae were included in RV mass. RV ejection fraction is calculated as (RV end-diastolic volume -RV end-systolic volume)/RV end-diastolic volume×100%. Immunofluorescent staining was performed using standard methods. In brief, sections were deparaffinized followed by epitope retrieval with antigen-unmasking solution (H3300, Vector Laboratories, Burlingame, CA). Blocking steps with 3% H 2 O 2 for endogenous peroxidase and 1% bovine serum albumin were performed before labeling with the primary antibodies O/N; phosphorylated (p) SMAD1,5,8 (CS9511, 1:200), p-SMAD2 (CS8828s, 1:100), von Willebrand Factor (used for capillary density analysis; A0082, DAKO, 1:100), CD45+ (used for inflammation analysis; M0701, DAKO, 1:200). Subsequent labeling with appropriate fluorescein isothiocyanate-conjugated secondary antibody followed von Willebrand Factor and CD45 labeling. Both p-SMAD1,5,8 and p-SMAD2 sections were labeled with appropriate horseradish peroxidase-conjugated secondary antibodies followed by tyramide signal amplification (NEL700A001KT, Perkin Elmer, Waltham, MA). All sections were counterstained with wheat germ agglutinin (W32464, Life Technologies, Carlsbad, CA) and 4′,6-diamidino-2 phenylindole (H-1200, Vector Laboratories, Burlingame, CA). Image acquisition was performed on a ZEISS Axiovert 200 mol/L Marianas inverted microscope. A minimum of 5 fields per section was randomly acquired for analysis. Slidebook 5.5 imaging analysis software (Intelligent Imaging Innovations, Denver, CO) was used to quantify for positive p-SMAD1,5,8 and p-SMAD2 nuclei and expresses as total number of p-SMAD-positive nuclei versus total nuclei count. CD45+ cells were expressed as the number of positive cells per area. Capillaries (von Willebrand Factor staining) and cardiomyocytes were semiautomatically counted and expressed as a number of capillaries per cardiomyocyte.
RNA Analysis
RNA was isolated from paraffin-embedded RV and LV tissues according to the manufacturer's protocol (73504, Qiagen, Venlo, The Netherlands) followed by purification (74204, Qiagen, Venlo, The Netherlands). Subsequently, RNA concentration and purity was assessed by using a Nanodrop spectrophotometer (Nanodrop 1000, Thermo Scientific, Breda, The Netherlands). Equal concentrations of RNA of all individual samples was reversely transcribed and amplified (3312-48, NuGEN, Leek, The Netherlands). Differential gene expression was assessed by quantitative real-time polymerase chain reaction using Takyon PCR mastermix (UF-LSMT-B0705, Eurogentec, Maastricht, The Netherlands) and the CFX96 Touch detection system (Bio-Rad, Veenendaal, The Netherlands). Relative levels of gene expression were obtained by using 18S rRNA as reference gene. Data are shown as fold change±standard error of the mean (SEM). Target genes, primers sequences, and annealing temperatures are shown in Table 1 .
Statistical Analysis
Statistical analyses were performed using Prism 5 for Windows (GraphPad Software Inc, San Diego, CA). The data are presented as means±SEM or median (25%-75%), dependent on normal distribution. Normal distribution was tested by using the D'Agostino and Pearson omnibus normality test. Values of P<0.05 were considered significant.
Differences in patient characteristics, hemodynamics, RV function, and RV histology were tested using a 1-way analysis of variance or Kruskal-Wallis test with proper post hoc comparison, depending on normal distribution. To compare categorical variables, a χ 2 test was used. Linear regression analysis was used to correct differences in RV function for PVR. Treatment response analysis was performed by using a 2-way analysis of variance with the Bonferroni multiple comparison test.
Cross-sectional area was analyzed by using multilevel analysis to correct for nonindependence of successive measurements per patients (MLwiN 2.02.03, Center for Multilevel Modeling, Bristol, UK).
Results
Patient Characteristics
Clinical characteristics of patients seen at the VU University Medical Center are presented in Table 2 and Table I in the online-only Data Supplement. No differences between carriers and noncarriers were found in sex or 6-minute walking distance. Mutation carriers tended to present at a younger age than noncarriers. 
BMPR2 Mutations
BMPR2 mutations were identified in 15 of 82 (18%) sporadic PAH patients and 13 of 21 (61%) familial PAH patients. Familial patients without BMPR2 mutation were excluded. Twenty different germline BMPR2 mutations were identified in the mutation carriers, including 3 large rearrangements (corresponding to an exon 1 deletion, a deletion of exons 4-12 and a deletion of exons 10-13) and 1 duplication of exon 8. (Table 3 )
Effects of BMPR2 Mutations on RV Function
To investigate whether BMPR2 mutations affect the RV, we first compared baseline hemodynamics of mutation carriers with noncarriers as presented in Table 2 and highlighted in Figure 2 . Time between RHC and MRI at baseline was 11±22 days in mutation carriers (79% within 7 days) and 10±30 days in noncarriers (82% within 7 days). Both measurements were obtained before the start of PAH-specific medication. Stroke volume index and cardiac index were lower in mutation carriers than in noncarriers, whereas no differences were found in mean pulmonary artery pressure, mean right atrial pressure, and mixed venous oxygen saturation.
Interestingly, CMR analysis showed that, despite the similar afterload, RV ejection fraction was lower in BMPR2 mutation carriers. RV volumes and RV mass were similar between groups. Also when corrected for PVR, RV ejection fraction remained significantly lower in BMPR2 mutation carriers than in noncarriers (P=0.028).
Treatment Response
To assess whether initial changes between mutation carriers and noncarriers at baseline remain after PAH-specific treatment, we performed a treatment response analysis in a subgroup of patients (Table II in . Time between RHC and MRI was 2±7 days in mutation carriers and 1±6 days in noncarriers. As can be appreciated from Table III in the online-only Data Supplement, both groups were treated equally. Initial differences between mutation carriers and noncarriers found at baseline (Table 2, Figure 2 ) continued to exist under treatment.
The Effects BMPR2 Mutations on TGF-β/BMP Signaling, RV Adaptation, and Cardiac Metabolism
To investigate whether the differences observed in the clinical data could be explained by differences in TGF-β or BMP signaling in cardiomyocytes, immunofluorescent staining and RNA analyses were performed in LV and RV tissue obtained from controls, mutation carriers, and noncarriers. Hemodynamic characteristics of tissue sample donors can be observed in Table 4 . Tissue samples of mutation carriers and noncarriers were matched on PVR to avoid load-dependent differences.
TGF-β/BMP Signaling
To assess BMP signaling, the first downstream effector of the BMP signaling cascade was stained, p-SMAD1,5,8 ( Figure 3A) . No difference was observed in p-SMAD1,5,8 expression in RV tissue of PAH and controls or between BMPR2 mutation carriers and noncarriers. However, expression of p-SMAD1,5,8 was significantly reduced in LV tissue of PAH patients in comparison with controls, although again no difference was found between BMPR2 mutation carriers and noncarriers.
To assess TGF-β activity, the expression of p-SMAD2 was determined ( Figure 3B ). Expression of p-SMAD2 was significantly reduced in PAH in comparison with both RV and LV tissue. However, no differences in p-SMAD2 activity were observed between BMPR2 mutation carriers and noncarriers.
No differences were observed in RNA expression of BMPR2 and the TGF-β type I receptor ( Figure 4A ), indicating that TGF-β and BMP activity are similar in cardiomyocytes in BMPR2 mutation carriers and noncarriers and that other factors may play a role in the different RV adaptation in mutation carriers and noncarriers.
RV Adaptation
To obtain more insight into the mechanisms of RV and LV adaptation, morphological characteristics of both noncarriers and mutation carriers were assessed. RV hypertrophy and LV atrophy was observed in all PAH patients in comparison with controls, without differences between mutation carriers and noncarriers ( Figure 5A ). In line with these data, increased expression of atrial natriuretic peptide was observed in PAH patients in comparison with controls, whereas expression was similar in carriers and noncarriers ( Figure 4B ).
RV fibrosis was increased in PAH patients in comparison with controls ( Figure 5B ). However, no differences were observed in RV fibrosis, capillary density, or CD45 expression in both RV and LV tissue of mutation carriers and noncarriers. (Figures 5B and 6 ).
In addition, the apoptotic rate (expression of caspase 3 and fas cell surface death receptor) was increased in PAH patients in comparison with controls, but similar between carriers and noncarriers ( Figure 4C ).
Cardiac Metabolism
To determine whether changes in metabolism may explain the differences in RV function between mutation carriers and noncarriers, we subsequently assessed RNA expression of the key components of glucose metabolism (GLUT1, hexokinase 1/2) and fatty acid oxidation (fatty acid binding protein 3 [FABP3] , CD36, carnitine palmitoyltransferase 1/2). Although significant increases in expression of GLUT 1, FABP3, and CPTB1 were observed in PAH tissue in comparison with control, no differences were identified between mutation carriers and noncarriers (Figure 7) . Data are presented as mean±SD or median (25%-75%), dependent on normal distribution. CI indicates cardiac index; HR, heart rate; LVEDVI, left ventricular end-diastolic volume index; LVEF, ejection fraction; LVESVI, left ventricular end-systolic volume index; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; 6MWD %pred, 6-min walking distance, % predicted; PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RVEDVI, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic volume index; SVI, stroke volume index; and Svo 2 , mixed venous oxygen saturation; *P value: comparison of mutation carriers vs noncarriers. by guest on August 31, 2017 http://circ.ahajournals.org/
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Discussion
By combining in vivo measurements of RV function with molecular and histological analyses of unique RV and LV tissue of PAH patients and controls, we were able to demonstrate that:
1. Despite a similar afterload, RV function is more severely compromised in BMPR2 mutation carriers than in noncarriers. Differences continue to exist after PAH-specific treatment. 2. TGF-β and BMP signaling is similar in LV and RV cardiomyocytes of BMPR2 mutation carriers and noncarriers. 3. The amount of RV hypertrophy, LV atrophy, fibrosis, apoptosis, inflammation, capillary density, and cardiac metabolism is similar between BMPR2 mutation carriers and noncarriers, indicating an equal RV and LV adaptation.
Impaired RV Function in BMPR2 Mutation Carriers
Previous large retrospective studies have demonstrated the increased hemodynamic burden in PAH patients carrying a BMPR2 mutation, accompanied by a shorter time to death or lung transplantation. 13, 14, [26] [27] [28] Until now, differences in survival and disease severity were mainly explained by a more severe pulmonary vascular involvement, leading to a more severe and faster disease trajectory. However, combining the fact that RV function is the main determinant of prognosis and disease severity and that the BMPR2 gene is also expressed in the RV, it can be speculated that RV function plays a role in the differential clinical phenotypes of mutation carriers and noncarriers. 4, 9, 29, 30 Accordingly, a recent study by Brittain et al 27 revealed an out-of-proportion RV dysfunction in HPAH patients at baseline. However, these differences should be interpreted with caution, as the afterload of mutation carriers was significantly higher in comparison with noncarriers.
An interesting finding in our present study is the comparable afterload of BMPR2 mutation carriers and noncarriers, suggesting a distinct clinical phenotype of BMPR2 mutation carriers in the Netherlands. A possible explanation is the relatively high percentage of cytoplasmic tail mutation carriers in our cohort, which is 25%, in comparison with 13% in the French PAH registry. 31 Because cytoplasmic tail mutation carriers present hemodynamically similarly to noncarriers, this may have contributed to the observed phenotype of our patient cohort. Despite these similarities, we observed a decreased RV function in mutation carriers. This reduction was not explained by differences in PVR or a more severe state of disease at presentation. These findings suggest a negative effect of BMPR2 mutations on RV function in PAH patients.
TGF-β/BMP Balance in PAH
Significant progress in the knowledge about the role of TGF-β in the response to pressure overload has been achieved by studies in left heart failure. Although it is known that TGF-β is associated with maladaptive hypertrophy, inflammation, and fibrosis in various models and diseases, the study of Koitabashi et al was the first to show that TGF-β plays a central role in the cardiac maladaptive response to pressure overload. [32] [33] [34] [35] [36] However, because the LV has a different embryological origin and the amount of pressure overload in right and left heart failure is not comparable, these results cannot be directly extrapolated. 37, 38 Until recently, little was known about the effects of BMPR2 mutations on RV adaptation in PAH. First, Megalou et al 39 showed the importance of TGF-β in the hypertrophic response in the myocardium of pulmonary hypertensive monocrotaline rats, and, more recently, Hemnes et al 24 demonstrated impaired hypertrophy attributable to an altered cardiac energy metabolism in the RV of a transgenic mice model expressing mutant BMP receptor II. However, the effects of BMPR2 mutations in human cardiomyocytes remain elusive. Therefore, we studied the TGF-β/BMP signaling in cardiomyocytes of PAH patients with and without BMPR2 mutation and characterized hypertrophy, capillarization, inflammation, and fibrosis. Surprisingly, our study did not reveal any differences in either TGF-β or BMP signaling between carriers and noncarriers, although it corresponds to a previous study of Atkinson et al, 16 in which they show a decreased BMP receptor II receptor expression in the pulmonary vasculature of both mutation carriers and noncarriers. Interestingly, we were able to demonstrate significant differences in BMPR2 expression and metabolic adaptation between noncarriers and controls, suggesting a potential dysfunctional compensatory signaling underlying the functional differences between mutation carriers and noncarriers. We were not able to confirm the previous observed RV maladaptive response in BMPR2 mice in our human RV tissue. One explanation might be the difference between rodents and human cardiac physiology. Another explanation could be the end-stage right heart failure of the patient samples used for our histomorphological analysis of the RV. There may be important differences in myocardial structure of failing and adapting RV, but, because of the inherent difficulties of obtaining biopsies (reported high complication rates) from adapted patients, this is problematic to assess.
Study Limitations
We were only able to include a small number of RV and LV tissue samples of PAH patients and controls. This may have limited our statistical power to identify differences between by guest on August 31, 2017 http://circ.ahajournals.org/ mutation carriers and noncarriers. However, we were able to confirm known differences in hypertrophy, fibrosis, and cardiac metabolism, which were described previously in animal models. [40] [41] [42] These findings suggest that, although the number of subjects was small, it was sufficient to identify differences between PAH and control subjects. 
Clinical Implications
Although a direct relation between RV function and a BMPR2 mutation was not revealed in this study, our findings suggest that BMPR2 mutations lead to an impaired RV function in symptomatic PAH. Our results raise the question whether clinical status and time to death or lung transplantation in BMPR2 mutation carriers could be improved by using the RV as a therapeutic target. Furthermore, our results provide rationale for closely monitoring RV function in BMPR2 mutation carriers in PAH referral centers and subsequently timely referral for lung transplantation. Further therapeutic studies targeting the disturbed TGF-β/BMP pathway will reveal the clinical implications of this disturbed balance in the RV of PAH patients. 
Conclusions
We demonstrated that PAH patients carrying a BMPR2 mutation have a decreased RV function in comparison with PAH patients without BMPR2 mutation at presentation, which persisted after PAH-specific treatment. We revealed that there are no alterations in TGF-β-and BMP-induced SMAD phosphorylation in the cardiomyocytes of PAH patients with or without mutation. Furthermore, we demonstrated that RV and LV adaptation is not different between BMPR2 mutation carriers and noncarriers. 
